Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

被引:8
作者
Gritsch, Herbert [1 ]
Schrenk, Gerald [1 ]
Weinhappl, Nina [1 ]
Mellgard, Bjorn [2 ]
Ewenstein, Bruce [2 ]
Turecek, Peter L. [3 ,4 ]
机构
[1] Baxalta Innovat GmbH, Pharmaceut Sci, Vienna, Austria
[2] Takeda Dev Ctr Amer Inc, Rare Genet & Hematol, Res & Dev, Cambridge, MA USA
[3] Univ Vienna, Dept Pharmaceut Sci, Div Pharmacol, Vienna, Austria
[4] Baxalta Innovat GmbH, Plasma Derived Therapies Res & Dev, Vienna, Austria
来源
JOURNAL OF BLOOD MEDICINE | 2022年 / 13卷
关键词
agar; electrophoresis; factor VIII; plasma; von Willebrand diseases; von Willebrand factor; VONWILLEBRAND-FACTOR; BINDING; MANAGEMENT; DIAGNOSIS; SAFETY;
D O I
10.2147/JBM.S377126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme.Purpose: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P (R)/ Humate-P (R), Voncento (R), Wilate (R)/Eqwilate (R), and Wilfactin (R)/Willfact (R); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF.Methods: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed.Results: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P (R), Voncento (R) and Wilate (R). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation.Conclusions: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy.
引用
收藏
页码:649 / 662
页数:14
相关论文
共 43 条
[1]   Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease [J].
Batlle, Javier ;
Fernanda Lopez-Fernandez, Maria ;
Loures Fraga, Esther ;
Rodriguez Trillo, Angela ;
Almudena Perez-Rodriguez, Maria .
BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (02) :89-100
[2]  
Bauer A, 2020, RES PRACT THROMB HAE, V4, P776
[3]  
Baxalta Innovations GmbH, VEYV SUMM PROD CHAR
[4]  
Baxalta US Inc, 2019, VONVENDI WILL FACT R
[5]   The Molecular Genetics of von Willebrand Disease [J].
Berber, Ergul .
TURKISH JOURNAL OF HEMATOLOGY, 2012, 29 (04) :313-324
[6]   Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD) [J].
Budde, U. ;
Schneppenheim, R. ;
Eikenboom, J. . ;
Goodeve, A. ;
Will, K. ;
Drewke, E. ;
Castaman, G. ;
Rodeghiero, F. ;
Federici, A. B. ;
Batlle, J. . ;
Perez, A. ;
Meyer, D. ;
Mazurier, C. ;
Goudemand, J. ;
Ingerslev, J. ;
Habart, D. ;
Vorlova, Z. ;
Holmberg, L. ;
Lethagen, S. ;
Pasi, J. ;
Hill, F. ;
Peake, I. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) :762-771
[7]   Comparative analysis and classification of von Willebrand factor/factor VIII concentrates:: Impact on treatment of patients with von Willebrand disease [J].
Budde, Ulrich ;
Metzner, Hubert J. ;
Mueller, Heinz-Georg .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (06) :626-635
[8]   Laboratory testing for von Willebrand Disease: Contribution of multimer analysis to diagnosis and classification [J].
Budde, Ulrich ;
Pieconka, Antje ;
Will, Kirsten ;
Schneppenheim, Reinhard .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (05) :514-521
[9]   In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor [J].
Colling, Meaghan E. ;
Friedman, Kenneth D. ;
Dzik, Walter H. .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
[10]   HETEROGENEITY OF PLASMA VONWILLEBRAND-FACTOR MULTIMERS RESULTING FROM PROTEOLYSIS OF THE CONSTITUENT SUBUNIT [J].
DENT, JA ;
GALBUSERA, M ;
RUGGERI, ZM .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (03) :774-782